TARGTEPO Treatment for Anemia in PD US Trial

NCT02468414 · clinicaltrials.gov ↗
PHASE2
Phase
TERMINATED
Status
3
Enrollment
INDUSTRY
Sponsor class

Stopped No statistical analysis was performed as only one subject was treated with MDGN201 TARGTEPO due to the Sponsor's decision to discontinue study.

Conditions

Interventions

Sponsor

Aevi Genomic Medicine, LLC, a Cerecor company

Collaborators